Ishares Msci Italy ETF vs Heron Therapeutics Inc — how do they compare? Ishares Msci Italy ETF trades at $55.99 (market cap $1.14B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: Ishares Msci Italy ETF is far larger — about 16.8× Heron Therapeutics Inc's market cap, and Ishares Msci Italy ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and Heron Therapeutics Inc for 35 Days on average.
| EWI | HRTX | |
|---|---|---|
Market Cap | $1.14B | $68.01M |
Volume | 2,377,947 | 1,891,941 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $1.49 |
52-Week Low | $50.31 | $0.27 |
Typical Hold Time | 52 Days | 35 Days |
Enterprise Value | — | $174.75M |
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →